Insecticides (India) is currently trading at Rs. 255.50, up by 8.05 points or 3.25% from its previous closing of Rs. 247.45 on the BSE.
The scrip opened at Rs. 255.00 and has touched a high and low of Rs. 262.00 and Rs. 255.00 respectively. So far 2466 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 431.00 on 23-Apr-2013 and a 52 week low of Rs. 203.00 on 08-Nov-2013.
Last one week high and low of the scrip stood at Rs. 262.00 and Rs. 245.00 respectively. The current market cap of the company is Rs. 324.05 crore.
The promoters holding in the company stood at 74.69% while Institutions and Non-Institutions held 6.35% and 18.96% respectively.
Insecticides (India) has been granted a patent by the Indian Patent Office for preparation process of Acetamiprid, an insecticide for sucking pests. The company had filed for process patents with India’s Controller General of Patents, Designs and Trademarks for eight chemical compounds, including Acetamiprid.
Besides, the company had recently tied up with Japan-based Otsuka AgriTechno Company to set up a joint venture for research and development of new agrochemical molecules.
Insecticides India’s leading agro-chemical and pesticides manufacturer. The company has formulation facilities in Chopanki in Rajasthan, Samba and Udhampur in Jammu & Kashmir and Dahej in Gujarat. It also has plants at Chopanki and Dahej to manufacture technical grade chemicals.
| Company Name | CMP |
|---|---|
| UPL | 665.00 |
| PI Industries | 3144.45 |
| Bayer CropScience | 4900.45 |
| Sharda Cropchem | 1109.70 |
| Sumitomo Chemical | 441.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: